Cargando…

Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19

BACKGROUND: Coronavirus disease 2019 (COVID-19) pneumonitis associated with severe respiratory failure is associated with high mortality. The pathogenesis of COVID-19 is associated with microembolism or microvascular endothelial injuries. Here, we report that syndecan-1 (SDC-1), a component of the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogawa, Fumihiro, Oi, Yasufumi, Nakajima, Kento, Matsumura, Reo, Nakagawa, Tomoki, Miyagawa, Takao, Sakai, Kazuya, Saji, Ryo, Taniguchi, Hayato, Takahashi, Kohei, Abe, Takeru, Iwashita, Masayuki, Nishii, Mototsugu, Takeuchi, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366156/
https://www.ncbi.nlm.nih.gov/pubmed/34399775
http://dx.doi.org/10.1186/s12959-021-00308-4
_version_ 1783738854675578880
author Ogawa, Fumihiro
Oi, Yasufumi
Nakajima, Kento
Matsumura, Reo
Nakagawa, Tomoki
Miyagawa, Takao
Sakai, Kazuya
Saji, Ryo
Taniguchi, Hayato
Takahashi, Kohei
Abe, Takeru
Iwashita, Masayuki
Nishii, Mototsugu
Takeuchi, Ichiro
author_facet Ogawa, Fumihiro
Oi, Yasufumi
Nakajima, Kento
Matsumura, Reo
Nakagawa, Tomoki
Miyagawa, Takao
Sakai, Kazuya
Saji, Ryo
Taniguchi, Hayato
Takahashi, Kohei
Abe, Takeru
Iwashita, Masayuki
Nishii, Mototsugu
Takeuchi, Ichiro
author_sort Ogawa, Fumihiro
collection PubMed
description BACKGROUND: Coronavirus disease 2019 (COVID-19) pneumonitis associated with severe respiratory failure is associated with high mortality. The pathogenesis of COVID-19 is associated with microembolism or microvascular endothelial injuries. Here, we report that syndecan-1 (SDC-1), a component of the endothelial glycocalyx, may be a biomarker of severity classification for COVID-19 related to endothelial injury. METHODS AND ANALYSIS: We analyzed the data of COVID-19 patients for 1 year from February 2020 at Yokohama City University Hospital and Yokohama City University Medical Center Hospital. We selected COVID-19 patients who required admission care, including intensive care, and analyzed the classification of severe and critical COVID-19 retrospectively, using various clinical data and laboratory data with SDC-1 by ELISA. RESULTS: We analyzed clinical and laboratory data with SDC-1 in five severe COVID-19 and ten critical COVID-19 patients. In the two groups, their backgrounds were almost the same. In laboratory data, the LDH, CHE, and CRP levels showed significant differences in each group (P = 0.032, P < 0.0001, and P = 0.007, respectively) with no significant differences in coagulation-related factors (platelet, PT-INR, d-dimer, ISTH score; P = 0.200, 0.277, 0.655, and 0.36, respectively). For the clinical data, the SOFA score was significantly different from admission day to day 14 of admission (p < 0.0001). The SDC-1 levels of critical COVID-19 patients were significantly higher on admission day and all-time course compared with the levels of severe COVID-19 patients (P = 0.009 and P < 0.0001, respectively). CONCLUSIONS: Temporal change of SDC-1 levels closely reflect the severity of COVID-19, therefore, SDC-1 may be a therapeutic target and a biomarker for the severity classification of Covid-19.
format Online
Article
Text
id pubmed-8366156
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83661562021-08-16 Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19 Ogawa, Fumihiro Oi, Yasufumi Nakajima, Kento Matsumura, Reo Nakagawa, Tomoki Miyagawa, Takao Sakai, Kazuya Saji, Ryo Taniguchi, Hayato Takahashi, Kohei Abe, Takeru Iwashita, Masayuki Nishii, Mototsugu Takeuchi, Ichiro Thromb J Research BACKGROUND: Coronavirus disease 2019 (COVID-19) pneumonitis associated with severe respiratory failure is associated with high mortality. The pathogenesis of COVID-19 is associated with microembolism or microvascular endothelial injuries. Here, we report that syndecan-1 (SDC-1), a component of the endothelial glycocalyx, may be a biomarker of severity classification for COVID-19 related to endothelial injury. METHODS AND ANALYSIS: We analyzed the data of COVID-19 patients for 1 year from February 2020 at Yokohama City University Hospital and Yokohama City University Medical Center Hospital. We selected COVID-19 patients who required admission care, including intensive care, and analyzed the classification of severe and critical COVID-19 retrospectively, using various clinical data and laboratory data with SDC-1 by ELISA. RESULTS: We analyzed clinical and laboratory data with SDC-1 in five severe COVID-19 and ten critical COVID-19 patients. In the two groups, their backgrounds were almost the same. In laboratory data, the LDH, CHE, and CRP levels showed significant differences in each group (P = 0.032, P < 0.0001, and P = 0.007, respectively) with no significant differences in coagulation-related factors (platelet, PT-INR, d-dimer, ISTH score; P = 0.200, 0.277, 0.655, and 0.36, respectively). For the clinical data, the SOFA score was significantly different from admission day to day 14 of admission (p < 0.0001). The SDC-1 levels of critical COVID-19 patients were significantly higher on admission day and all-time course compared with the levels of severe COVID-19 patients (P = 0.009 and P < 0.0001, respectively). CONCLUSIONS: Temporal change of SDC-1 levels closely reflect the severity of COVID-19, therefore, SDC-1 may be a therapeutic target and a biomarker for the severity classification of Covid-19. BioMed Central 2021-08-16 /pmc/articles/PMC8366156/ /pubmed/34399775 http://dx.doi.org/10.1186/s12959-021-00308-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ogawa, Fumihiro
Oi, Yasufumi
Nakajima, Kento
Matsumura, Reo
Nakagawa, Tomoki
Miyagawa, Takao
Sakai, Kazuya
Saji, Ryo
Taniguchi, Hayato
Takahashi, Kohei
Abe, Takeru
Iwashita, Masayuki
Nishii, Mototsugu
Takeuchi, Ichiro
Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19
title Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19
title_full Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19
title_fullStr Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19
title_full_unstemmed Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19
title_short Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19
title_sort temporal change in syndecan-1 as a therapeutic target and a biomarker for the severity classification of covid-19
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366156/
https://www.ncbi.nlm.nih.gov/pubmed/34399775
http://dx.doi.org/10.1186/s12959-021-00308-4
work_keys_str_mv AT ogawafumihiro temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT oiyasufumi temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT nakajimakento temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT matsumurareo temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT nakagawatomoki temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT miyagawatakao temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT sakaikazuya temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT sajiryo temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT taniguchihayato temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT takahashikohei temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT abetakeru temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT iwashitamasayuki temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT nishiimototsugu temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19
AT takeuchiichiro temporalchangeinsyndecan1asatherapeutictargetandabiomarkerfortheseverityclassificationofcovid19